ATC Group: J04AK01 Pyrazinamide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J04AK01 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J04 Antimycobacterials
3 J04A Drugs for treatment of tuberculosis
4 J04AK Other drugs for treatment of tuberculosis
5 J04AK01 Pyrazinamide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1.5 g

Active ingredients in J04AK01

Active Ingredient Description
Pyrazinamide

Pyrazinamide exhibits tuberculostatic activity. Pyrazinamide is active only at an acid pH, and it is therefore active mainly on the tubercle bacilli located within the cell.

Related product monographs

Title Information Source Document Type  
ZINAMIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Japan (JP)

Lithuania (LT)

Malta (MT)

South Africa (ZA)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.